Endosome associated trafficking regulator 1 promotes tumor growth and invasion of glioblastoma multiforme via inhibiting TNF signaling pathway-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Endosome associated trafficking regulator 1 promotes tumor growth and invasion of glioblastoma multiforme via inhibiting TNF signaling pathway

Published:2024-01 Issue:1 Volume:166 Page:113-127
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Zhang Qian,Dai Zhang’an,Chen Yingyu,Li Qun,Guo Yuhang,Zhu Zhangzhang,Tu Ming,Cai Lin,Lu Xianghe

Funder

Department of Health of Zhejiang Province of China

Wenzhou Municipal Science and Technology Bureau of China

Basic scientific research Project of Wenzhou Medical University of China

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11060-023-04527-9.pdf

Reference45 articles.

1. Poon M, Bruce M, Simpson J, Hannan C, Brennan P (2021) Temozolomide sensitivity of malignant glioma cell lines—a systematic review assessing consistencies between in vitro studies. BMC Cancer 21(1):1240. https://doi.org/10.1186/s12885-021-08972-5

2. Pająk B (2022) Looking for the holy grail-drug candidates for glioblastoma multiforme chemotherapy. Biomedicines 10(5):1001. https://doi.org/10.3390/biomedicines10051001

3. Caccese M, Simonelli M, Villani V, Rizzato S, Ius T, Pasqualetti F et al (2022) Definition of the prognostic role of MGMT promoter methylation value by pyrosequencing in newly diagnosed IDH wild-type glioblastoma patients treated with radiochemotherapy: a large multicenter study. Cancers 14(10):2425. https://doi.org/10.3390/cancers14102425

4. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003. https://doi.org/10.1056/NEJMoa043331

5. Hegi ME, Genbrugge E, Gorlia T, Stupp R, Gilbert MR, Chinot OL et al (2019) MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: a pooled analysis of four clinical trials. Clin Cancer Res 25(6):1809–1816. https://doi.org/10.1158/1078-0432.CCR-18-3181

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3